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The incidence of mortality of prostate cancer (PCa) has been an uptrend in recent years. Our previous study showed that the sex-determining region Y-box 7 (SOX7) was low-expressed and served as a tumor suppressor in PCa cells. Here, we describe the effects of polyphyllin D (PD) on proliferation and cell cycle modifications of PCa cells, and whether SOX7 participates in this process. PC-3 cells were cultured in complete medium containing PD for 12, 24, and 48 h. MTT assay was used to investigate the cytotoxic effects of PD. Cell cycle progression was analyzed using propidium iodide (PI) staining, and protein levels were assayed by Western blot analysis. Our results showed low expression of SOX7 in PCa tissues/cells compared to their non-tumorous counterparts/ RWPE-1 cells. Moreover, PD inhibited the proliferation of PC-3 cells in a dose-and time-dependent manner. PD induced G0/G1 cell cycle arrest, while co-treatment with short interfering RNA targeting SOX7 (siSOX7) had reversed this effect. PD downregulated SOX7, cyclin D1, cyclin-dependent kinase 4 (CDK4), and cyclin-dependent kinase 6 (CDK6) expressions in a dose-dependent manner, whereas co-treatment of siSOX7 and PD rescued the PD-inhibited cyclin D1 expression. However, no obvious changes were observed in CDK4 or CDK6 expression. These results indicate that SOX7 is involved in PD-induced PC-3 cell cycle arrest through down-regulation of cyclin D1.
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The herb Paris polyphylla is a traditional Chinese drug that has heat-clearing and detoxicating effects. Polyphyllin D (PD) is the major component of Paris polyphylla, and it has been used to treat such ailments as convulsions, mastitis, and tumors of the respiratory system, as well as leukemia (3, 4, 5) . Studies have shown that PD functions as an anti-tumor agent through the inhibition of cell proliferation and by inducing apoptosis in several tumor cell types (5, 6, 7) . However, none of the studies have evaluated the cytotoxicity of PD against PCa. Our preliminary results have indicated that PD exerts potent cytotoxicity effect against PCa cells in the MTT assay, but the underlying molecular mechanisms of the process have not yet been elucidated.
The transcription factor sex-determining region Y-box 7 (SOX7) is a member of the SRY-related high-mobility group box (SOX) family, located on chromosome 8 (8p22). SOX7, together with SOX17 and SOX18, comprises the SOXF subfamily, which participates in various biological processes, including the regulation of vasculogenesis (8), hematopoiesis (9), cardiogenesis (10), and myogenesis (11) . Studies have reported that SOX7 acts as a tumor suppressor in the breast (12) , lung (13) , colorectal (14) , liver (15) , and gastric cancers (16) . Guo et al. (17) reported that tumor suppressor SOX7 functions as an independent checkpoint for beta-catenin transcriptional activity in PCa . Our previous study showed that SOX7 is expressed at low levels and inhibits PC-3 cell proliferation, cell cycle, migration, and invasion (18) . However, whether SOX7 participated in the inhibition effect of PD-treated PCa cells remains unknown. This study, therefore, aims to explore the role of SOX7 on cell proliferation and cell cycle changes in PD-treated PCa cells.
EXPERIMENTAL

Reagents
PD was purchased from Nanjing Spring&Autumn Biological Engineering Co., Ltd. (China). The purified PD (> 98 %) was dissolved in methanol at 10 mmol L -1 as a stock solution. The working solution was collected in a basal medium with the final methanol concentration of 0.05 %. The controls were also treated with an equal amount of methanol as used in the corresponding experiments. The MTT assay kit was purchased from Promega (USA). Propidium iodide (PI) and Cell cycle detection kit were bought from Beyotime Co., Ltd. (China). All chemicals used in this study were reagent grade and commercial products.
Cell culture
PC-3 and human prostate epithelial cell line RWPE-1 were obtained from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (China). PC-3 cells were cultured in an F-12 medium (Gibco, USA), and RWPE-1 cells were cultured in a K-SFM medium (Invitrogen, USA). Both media were supplemented with 10 % inactivated fetal bovine serum (Hyclone, New Zealand), 100 mg mL -1 of penicillin (Hyclone) and 100 U mL -1 of streptomycin (Hyclone). All cells were incubated at 37 °C in 5 % CO 2 .
Cell viability assay
MTT assay was used to evaluate PC-3 cell viability after treatment with various concentrations of PD (0 (control), 0.01, 0.1, 1.0, or 10.0 µmol L -1 ). Cells were seeded in 96-well plates at a concentration of 1.0 × 10 4 cells/well, followed by incubation at 37 °C in 5 % CO 2 . Subsequent to 0, 12, 24 and 48 h of incubation, 20 µL of CellTiter 96 Aqueous One Solution Reagent was added to each well. The absorbance at 492 nm was measured using a spectrophotometer.
Cell transfection
Cells were transfected with siSOX7 (GenePharma, China) using lipofectamine TM 2000 (Invitrogen, USA), according to the manufacturer's protocol. After 24 h transfection, cells were treated with PD and cultured for another 24 h, prior to collection for further analysis (19) .
Western blot
Cells were harvested and lysed with radioimmunoprecipitation assay (RIPA) buffer (Solarbio, China) containing 1 % protease inhibitor phenylmethanesulfonyl fluoride (PMSF) (Solarbio). Total protein concentrations were measured by bicinchoninic acid (BCA) protein Assay (Beyotime, China). For the Western blot, 30 µg of protein from each sample was subjected to 12 % SDS-PAGE, transferred electrophoretically to polyvinylidene difluoride (PVDF) membranes, and subsequently blocked with 5 % non-fat dry milk (blocking buffer). PVDF membranes were incubated overnight at 4 °C with the following specific primary antibodies: Cyclin D1 (#2987), CDK4 (#2906), CDK6 (#3136), P21 (#2946), P27 (#2552), and GAPDH (#5174) (CST, USA, dilution 1:800), and SOX7 (ab89954) (Abcam, UK, dilution 1:800). Horseradish peroxidase (HRP) labeled secondary antibody including goat anti-mouse IgG-HRP (BA1051) or goat anti-rabbit IgG-HRP (BA1055) (Boster, China, dilution 1:5,000) was incubated for 2 h at room temperature. Specific antibody binding was visualized using enhanced chemiluminescence reagent (20) . Tanon GIS software (Tanon, China) was used to calculate the band intensity of each protein.
Cell cycle assay
To determine the distribution of cell cycle stages, cells were washed with phosphate buffer saline (PBS) and fixed with chilled 100 % ethanol for 24 h. The fixed cells were stained with PI, and flow cytometric analysis was then performed by a FACSCalibur flow cytometer (Becton Dickinson, USA). Data were analyzed using the MODFIT software (USA) (21) .
Tissue samples
Pair-matched PCa and their adjacent non-tumor tissues were obtained from the pathology department of Ningbo Yinzhou Second Hospital. The informed consent was obtained by each patient and study protocol was approved by Ethical Committee of Ningbo Yinzhou Second Hospital.
Statistical analysis
All data were shown as means ± standard deviation (SD) of three independent experiments. Groups were statistically compared by one-way analysis of variance with Dunnett's test or unpaired Student's t-test. p < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
Current PCa therapies have limited effectiveness and safeness in the clinic due to intolerable side-effects present in most cases (2) . During the past several years, the overall survival rate of PCa remained stagnant even in patients treated with combined chemotherapy and radiotherapy. In addition, the systemic toxicity of the chemotherapeutic agents, which patients cannot easily tolerate, has limited their application in the clinic (22) . Therefore, the search for novel therapeutic drugs with improved clinical efficacy and safety for PCa treatment is highly desired.a Natural products and their extracts are being studied as new and promising resources for anti-PCa drugs. Recently, PD (Fig. 1a) has attracted a great deal of attention due to its ability to directly trigger mitochondrial membrane permeabilization and to induce apoptosis (23) . However, to our knowledge, little has been determined about its effect on PC-3 cells. Here, we examined PD-treated PC-3 cells and found that PD substantially inhibited the cell viability of PC-3 cells in a time-and concentration-dependent manner (Fig. 1b) .
Cyclins participate in the control of the cell cycle progression by activating CDKs (24, 25) . During the G1 phase, cyclin D1 forms a complex with CDK4 or CDK6 and promotes the cell cycle progression from G0/G1 phase to S phase (26) . However, cyclin-dependent kinase inhibitors (CDKIs) can especially recognize and bind with the cyclins/CDKs complex, thus inhibiting their activities and regulating the cell cycle progression. The G1-S transition could be regulated by CDKIs, such as P21 and P27, through inhibition of cyclins/ CDKs activities (27) . Therefore, direct or indirect regulation of cyclins through up-regulation of CDKIs is a potential approach to determine the cell cycle progression. In the present study, we found that the treatment with PD had caused G0/G1 phase arrest and decreased the expressions of cyclin D1, CDK4, and CDK6, while no significant changes in P21 and P27 levels were observed ( Fig. 2 and Fig. 3 ). However, it remains unknown which of the downstream nuclear effectors participate in the process of PD-reduced cyclin D1/CDKs complexes activities.
Emerging evidence has suggested that SOX7 is downregulated in various types of cancer tissues relative to their non-tumorous counterparts (19, (28) (29) (30) . Our results also showed SOX7 to be expressed at lower levels in PCa tissues than in adjacent non-tumor tissue ( Fig. 4) , indicating that SOX7 acts as a tumor suppressor in PCa progression. In addition, Wang et al. (31) showed that ectopic-expression of SOX7 reduced cell proliferation in renal cancer cells, whereas knockdown of SOX7 promoted it. Chan et al. (32) reported SOX7 to be a negative upstream regulator of the Wnt targets, including cyclin D1 and cmyc, in endometrial cancer cells. Similar results were also observed in ovarian, colorectal, and liver cancer cells (30, 33) . Cyclin D1 acts as a growth sensor and provides a link between mitogenic stimuli and the cell cycle (34) . SOX7 could control G1/S progression by regulating cyclin D1 and c-myc, but has no marked influence on CDK4 and CDK6 expression levels in liver cancer cells (35, 36) .
Here, we addressed whether SOX7 is involved in PD-induced G0/G1 cell cycle arrest in PCa cells. Our results showed that PD was capable of rising SOX7 levels in a dose--dependent manner (Fig. 5) . To confirm the role of SOX7 in PD-induced changes in the cell cycle, we transfected cells with siSOX7 to silence the SOX7 levels ( Fig. 6a and b ). Flow cytometer data showed that PD markedly increased the number of cells in the G0/G1 phase, while co-treatment of siSOX7 and PD reversed PD-induced G0/G1 cell cycle arrest ( Fig. 6c  and d) . Moreover, the addition of siSOX7 also rescued PD-inhibited cyclin D1 expression, while no obvious changes were observed in PD-inhibited CDK4 and CDK6 ( Fig. 6e and f) . These results suggest that cyclin D1, but not CDK4 and CDK6, is regulated by SOX7 in PCa cells, which is consistent with previous studies researched in liver cancer (35) . Taken together, these data indicate that SOX7-mediated PD-induced cell cycle arrest in the G0/G1 phase is associated with changes in cyclin D1 expressions. CONCLUSIONS These results demonstrate that SOX7 is involved in PD-induced G0/G1 cell cycle arrest by downregulation of cyclin D1 expression. However, further research is needed to fully characterize the biological functions of SOX7 and its clinical relevance in the development of PCa. Collectively, SOX7 may be a potential therapeutic target by PD, and further indepth studies are needed to focus on the safety of PD in PCa therapies.
